MIRA Pharmaceuticals announced that its Phase 2a clinical program for Ketamir-2 in chemotherapy-induced peripheral neuropathy has advanced toward site initiation following FDA review. The company incorporated regulatory feedback into the protocol, which is now under Institutional Review Board review at a leading cancer research institution. Site initiation is targeted for the first quarter of 2027. MIRA Pharmaceuticals operates as a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics.
